Keitner G I, Haier R J, Qualls C B, Brown W A, McKendall M J
Psychiatry Res. 1985 Mar;14(3):215-23. doi: 10.1016/0165-1781(85)90016-2.
There is uncertainty about the clinical usefulness of the dexamethasone suppression test (DST). It is also unclear whether there are advantages to a 1-mg or 2-mg DST. Eighty-three consecutive psychiatric inpatients were randomly given a 1-mg or 2-mg DST within the first week of admission. Sensitivity, specificity, and diagnostic confidence are reported for this group, and also in combination with those for 119 semi-consecutive psychiatric admissions. Although rates of nonsuppression were consistently higher in patients with affective disorders than in patients with other diagnoses, the diagnostic confidence of the DST for major depression in a diverse and unselected patient population was not greater than the prevalence of the disorder. The DST does not appear to be useful for clinical diagnostic decision-making. Nonetheless, the DST may still be an important biological marker in neuroendocrine psychiatric research.
地塞米松抑制试验（DST）的临床实用性存在不确定性。1毫克或2毫克剂量的DST是否具有优势也尚不清楚。83名连续入院的精神科住院患者在入院第一周内被随机给予1毫克或2毫克的DST。报告了该组的敏感性、特异性和诊断置信度，并将其与119名半连续精神科住院患者的相应数据相结合。尽管情感障碍患者的不抑制率始终高于其他诊断的患者，但在多样化且未经筛选的患者群体中，DST对重度抑郁症的诊断置信度并不高于该疾病的患病率。DST似乎对临床诊断决策没有用处。尽管如此，DST在神经内分泌精神病学研究中可能仍然是一个重要的生物学标志物。
